A Modern In Vivo Pharmacokinetic (PK) Paradigm: Combining Snapshot, Rapid And Full PK Approaches To Support Early Drug Discovery | 50169
Journal of Clinical Trials
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Successful drug discovery relies on selection of drug candidates with good in vitro ADME and in vivo pharmacokinetic properties
as well as appropriate preclinical efficacy and safety profiles. However, in vivo animal pharmacokinetic studies are still conducted
in a traditional low throughput manner, and therefore, are often the bottlenecks of discovery projects in many pharmaceutical
companies. This presentation will focus on the tiered in vivo PK approaches, including snapshot PK, rapid PK and full PK study
designs which we have implemented to support our drug discovery efforts. In all 3 approaches, compound is dosed and analyzed
discretely, thereby eliminating any drug-drug interaction concerns and analysis complications typically associated with cassette
dosing or cassette analysis. The rapid PK approach uses several integrated and automated processes and sample pooling strategy
to improve throughput, and has become our main stream PK approach in the lead optimization stage. These in vivo PK
approaches differ in throughputs, capacities, the resources required, and are designed to address the varying needs of drug discovery
projects at different stages of project progression. These approaches are well integrated within discovery research, allow tremendous
flexibility and are highly efficient in supporting the diverse needs and increasing demand for in vivo profiling. Examples of each of the
tiered in vivo PK studies will be illustrated.
Chun Li has completed her MS on Analytical Chemistry from University of Waterloo, Canada. She has worked in DMPK groups within 3 different Pharmaceutical companies for over 25 years. She first joined Merck Research Laboratories in Canada in the year 1990, and then moved to Amgen in 2001 supporting both Discovery and Development DMPK. In 2008, she joined Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, supporting discovery projects. She has authored or co-authored more than 35 papers in reputed journals and is a member of American Association of Pharmaceutical Scientists (AAPS).